Neuroblastoma is a childhood cancer caused by the transformation of sympathoadrenal progenitors. By following the formation of tumors in homozygous TH-MYCN mice, an established mouse model of neuroblastoma, we were able to capture transformed cells prior to the formation of large, vascularized tumors in order to determine the responsiveness of cells to neurotrophic factors. We discovered that the ciliary neurotrophic factor (CNTF) receptor is abundantly expressed in tumor cells from these mice. Furthermore, CNTF - but not nerve growth factor, brain-derived nerve growth factor, neurotrophin 3, or glial cell line-derived neurotrophic factor - promoted neuronal differentiation and withdrawal from the cell cycle. Thus, the transformation of sympathoadrenal progenitors by MYCN overexpression differentially affects responsiveness to neurotrophic molecules.

Keywords:
Neurite growth, Differentiation, Neuroblastoma, Neurotrophic factor, Neurotrophin
1.
Maris JM, Hogarty MD, Bagatell R, Cohn SL: Neuroblastoma. Lancet 2007;369:2106-2120.
2.
Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM: Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 1994;14:759-767.
3.
Lavenius E, Gestblom C, Johansson I, Nanberg E, Pahlman S: Transfection of TRK-A into human neuroblastoma cells restores their ability to differentiate in response to nerve growth factor. Cell Growth Differ 1995;6:727-736.
4.
Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P, Camoratto AM, Evans AE, Brodeur GM: Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 2002;62:6462-6466.
5.
Ho R, Minturn JE, Hishiki T, Zhao H, Wang Q, Cnaan A, Maris J, Evans AE, Brodeur GM: Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res 2005;65:9868-9875.
6.
Cohen PS, Letterio JJ, Gaetano C, Chan J, Matsumoto K, Sporn MB, Thiele CJ: Induction of transforming growth factor beta 1 and its receptors during all-trans-retinoic acid (RA) treatment of RA-responsive human neuroblastoma cell lines. Cancer Res 1995;55:2380-2386.
7.
Davis S, Aldrich TH, Stahl N, Pan L, Taga T, Kishimoto T, Ip NY, Yancopoulos GD: LIFRβ and GP130 as heterodimerizing signal transducers of the tripartite CNTF receptor. Science 1993;260:1805-1808.
8.
Eckenstein FP, Esch F, Holbert T, Blacher RW, Nishi R: Purification and characterization of a trophic factor for embryonic peripheral neurons: comparison with fibroblast growth factors. Neuron 1990;4:623-631.
9.
Ip NY, Li YP, van de Stadt I, Panayotatos N, Alderson RF, Lindsay RM: Ciliary neurotrophic factor enhances neuronal survival in embryonic rat hippocampal cultures. J Neurosci 1991;11:3124-3134.
10.
Lehwalder D, Jeffrey PL, Unsicker K: Survival of purified embryonic chick retinal ganglion cells in the presence of neurotrophic factors. J Neurosci Res 1989;24:329-337.
11.
Miller RG, Bryan WW, Dietz MA, Munsat TL, Petajan JH, Smith SA, Goodpasture JC: Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis. Neurology 1996;47:1329-1331.
12.
Stöckli KA, Lottspeich F, Sendtner M, Masiakowski P, Carroll P, Götz R, Lindholm D, Thoenen H: Molecular cloning, expression and regional distribution of rat ciliary neurotrophic factor. Nature 1989;342:920-923.
13.
Kirsch M, Hofmann HD: Expression of ciliary neurotrophic factor receptor mRNA and protein in the early postnatal and adult rat nervous system. Neurosci Lett 1994;180:163-166.
14.
Finn T, Nishi R: Does ciliary neurotrophic factor serve a different function in the rat versus the chicken? Perspect Dev Neurobiol 1996;4:91-99.
15.
Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM: Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997;16:2985-2995.
16.
Hansford LM, Thomas WD, Keating JM, Burkhart CA, Peaston AE, Norris MD, Haber M, Armati PJ, Weiss WA, Marshall GM: Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc Natl Acad Sci USA 2004;101:12664-12669.
17.
Alam G, Cui H, Shi H, Yang L, Ding J, Mao L, Maltese WA, Ding HF: MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development. Am J Pathol 2009;175:856-866.
18.
Moore HC, Wood KM, Jackson MS, Lastowska MA, Hall D, Imrie H, Redfern CP, Lovat PE, Ponthan F, O'Toole K, Lunec J, Tweddle DA: Histological profile of tumours from MYCN transgenic mice. J Clin Pathol 2008;61:1098-1103.
19.
Hackett CS, Hodgson JG, Law ME, Fridlyand J, Osoegawa K, de Jong PJ, Nowak NJ, Pinkel D, Albertson DG, Jain A, Jenkins R, Gray JW, Weiss WA: Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res 2003;63:5266-5273.
20.
Weiss WA, Godfrey T, Francisco C, Bishop JM: Genome-wide screen for allelic imbalance in a mouse model for neuroblastoma. Cancer Res 2000;60:2483-2487.
21.
Chesler L, Goldenberg DD, Seales IT, Satchi-Fainaro R, Grimmer M, Collins R, Struett C, Nguyen KN, Kim G, Tihan T, Bao Y, Brekken RA, Bergers G, Folkman J, Weiss WA: Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res 2007;67:9435-9442.
22.
Storey KG, Crossley JM, de Robertis EM, Norris WE, Stern CD: Neural induction and regionalisation in the chick embryo. Development 1992;114:729-741.
23.
Heller S, Ernsberger U, Rohrer H: Extrinsic signals in the developing nervous system: the role of neurokines during neurogenesis. Perspect Dev Neurobiol 1996;4:19-34.
24.
Ip NY, McClain J, Barrezueta NX, Aldrich TH, Pan L, Li Y, Wiegand SJ, Friedman B, Davis S, Yancopoulos GD: The alpha component of the CNTF receptor is required for signaling and defines potential CNTF targets in the adult and during development. Neuron 1993;10:89-102.
25.
Ernsberger U, Sendtner M, Rohrer H: Proliferation and differentiation of embryonic chick sympathetic neurons: effects of ciliary neurotrophic factor. Neuron 1989;2:1275-1284.
26.
Yu CC, Woods AL, Levison DA: The assessment of cellular proliferation by immunohistochemistry: a review of currently available methods and their applications. Histochem J 1992;24:121-131.
27.
Doering LC, Roder JC, Henderson JT: Ciliary neurotrophic factor promotes the terminal differentiation of v-myc immortalized sympathoadrenal progenitor cells in vivo. Brain Res Dev Brain Res 1995;89:56-66.
28.
Rossino P, Volpe G, Negro A, Callegaro L, Altruda F, Tarone G, Silengo L: Ciliary neurotrophic factor-induced gene expression in human neuroblastoma cell lines. Neurochem Res 1995;20:675-680.
29.
Squinto SP, Aldrich TH, Lindsay RM, Morrissey DM, Panayotatos N, Bianco SM, Furth ME, Yancopoulos GD: Identification of functional receptors for ciliary neurotrophic factor on neuronal cell lines and primary neurons. Neuron 1990;5:757-766.
30.
Halvorsen SW, Malek R, Wang X, Jiang N: Ciliary neurotrophic factor regulates nicotinic acetylcholine receptors on human neuroblastoma cells. Neuropharmacology 1996;35:257-265.
31.
Bogenmann E, Peterson S, Maekawa K, Matsushima H: Regulation of NGF responsiveness in human neuroblastoma. Oncogene 1998;17:2367-2376.
32.
Slamon DJ, Boone TC, Seeger RC, Keith DE, Chazin V, Lee HC, Souza LM: Identification and characterization of the protein encoded by the human N-myc oncogene. Science 1986;232:768-772.
33.
Thomas WD, Raif A, Hansford L, Marshall G: N-myc transcription molecule and oncoprotein. Int J Biochem Cell Biol 2004;36:771-775.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.